Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 43,346 shares at $3.95 ($171K) on 2022-05-16, disclosed to the SEC on 2022-05-17.
Open-market sale of $171k NKTR by Chief R&D Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.95 | 21,673 | $86K | 50.0% |
| 2 | $3.95 | 21,673 | $86K | 50.0% |
| Total | $3.95 avg | 43,346 | $171K | 100% |
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |